Larry Anderson, MD, PhD, Discusses CAR T-Cell Therapy For Multiple Myeloma at 2021 IMW

Video

CancerNetwork® sat down with Larry Anderson, MD, PhD, at the 18th International Myeloma Workshop to talk about how the emergence of CAR T-cell therapies in multiple myeloma affects multidisciplinary clinicians.

At the 18th Annual International Multiple Myeloma Workshop, CancerNetwork® spoke with Larry Anderson, MD, PhD, of UT Southwestern, about the real-world considerations of CAR T-cell therapy administration in patients with multiple myeloma. Anderson explained the advantage of having a multidisciplinary team of clinicians who are trained in managing patients on CAR T-cell therapy.

Transcript:

First, one thing to highlight is that CAR T-cell therapy, although it works very well, does have specific toxicities that one has to be experienced with to be able to give this therapy. Right now, it’s [administration is] limited to large referral centers like bone marrow transplant centers and academic medical centers that have expertise with stem cell and cell therapies. These products involve a lot of disciplines. We have social workers for these patients, and we have a lot of different team members helping to make sure this [treatment] goes smoothly.

For example, because of the risk of neurotoxicity and risk of seizures with any CAR T-cell product, these patients can’t drive for 2 months. They must have a caregiver who can bring them to appointments. They must have wallet cards to let providers know [to send] them somewhere else that if they have fevers or symptoms of cytokine release syndrome or neurotoxicity. [These cards] will have our contact information and let [providers] know that those patients need to get to our center as soon as possible. These patients generally will need to live within a couple hours of the medical center for the first month. It does impact a lot of their lifestyle, but I would say the biggest impact is after the first month, once these patients are off therapy for the first time in many years [or even] a decade, they enjoy not being on treatment for the coming years after the CAR T-cell infusion. They really enjoy the freedom that that brings.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content